French
DeutschCentpropazine
 | |
| Clinical data | |
|---|---|
| Other names | CPZ; CTZ |
| Routes of administration | Oral[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C22H28N2O3 |
| Molar mass | 368.477 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Centpropazine (CPZ, CTZ) is an experimental antidepressant which was under development for the treatment major depressive disorder in India but was never marketed.[1][2][3] It is described as having imipramine-like clinical effects, reversing reserpine-induced effects in animals, and potentiating amphetamine-induced effects in animals.[3] The mechanism of action of centpropazine is unknown.[4] The drug reached phase 3 clinical trials prior to the discontinuation of its development.[1] It was first described in the scientific literature by 1980.[3][5]
References
[edit]- ^ a b c "Centpropazine". AdisInsight. Springer Nature Switzerland AG. 10 December 2013. Retrieved 27 September 2024.
- ^ Avasthi A, Grover S, Aggarwal M (January 2010). "Research on antidepressants in India". Indian Journal of Psychiatry. 52 (Suppl 1): S341–S354. doi:10.4103/0019-5545.69263. PMC 3146188. PMID 21836704.
- ^ a b c Kaiser C, Bondinell WE (1981). "Chapter 1. Antidepressants". Annual Reports in Medicinal Chemistry. Vol. 16. Elsevier. p. 1–10. doi:10.1016/s0065-7743(08)61268-3. ISBN 978-0-12-040516-9. ISSN 0065-7743.
- ^ shrafuzzaman M, Ji SH, Ahn H, Chung HW, Choi D, Park JJ, Go M, Pyo JI, Shafioul AS, Lee DH, Chi SG (29 March 2023). "Identification of 1-phenoxy-3-(piperazin-1-yl)propan-2-ol derivatives as novel triple reuptake inhibitors". Bulletin of the Korean Chemical Society. 44 (7). Wiley: 596–599. doi:10.1002/bkcs.12693. ISSN 1229-5949.
- ^ Singh H, Chawla AS, Kapoor VK (1985). "Medicinal chemistry research in India". Progress in Medicinal Chemistry. 22: 243–266. doi:10.1016/s0079-6468(08)70232-7. ISBN 978-0-444-80668-0. PMID 2873624.